Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes

Acta Diabetologica

Volumn 52, Issue 1, 2015, Pages 113-122

  Bogdanov, Patricia ^a,b   Hernández, Cristina ^a,b   Corraliza, Lidia ^a,b   Carvalho, Andrea R ^a,c   Simó, Rafael ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Diabetic mouse model; Diabetic retinopathy; Fenofibrate; Neurodegeneration

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 1; FENOFIBRATE; FENOFIBRIC ACID; SLC1A3 PROTEIN, MOUSE;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; COMPLICATION; DIABETIC RETINOPATHY; DISEASE MODEL; DRUG EFFECTS; HUMAN; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RETINAL DEGENERATION;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID TRANSPORTER 1; FENOFIBRATE; HUMANS; MALE; MICE; RETINAL DEGENERATION;

EID: 84939874101     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0610-2     Document Type: Article

References (39)

1. Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376:124–136
2. Mohamed Q, Gillies MC, Wong TY (2007) Management of diabetic retinopathy: a systematic review. JAMA 298:902–916
3. Simó R, Hernández C (2009) Advances in the medical treatment of diabetic retinopathy. Diabetes Care 32:1556–1562
4. Rosenson RS (2008) Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 6:1319–1330
5. Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d’Emden MC, Crimet DC, O’Connell RL, Colman PG, FIELD Study Investigators (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370:1687–1697
6. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:233–244
7. Wong TY, Simó R, Mitchell P (2012) Fenofibrate—a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 154:6–12
8. Simo R, Roy S, Behar-Cohen F, Keech A, Mitchell P, Wong TY (2013) Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. Curr Med Chem 20:3258–3266
9. Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, Shinn SH, Oh YS (2007) Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 84:886–893
10. Villarroel M, Garcia-Ramírez M, Corraliza L, Hernández C, Simó R (2011) Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia 54:1543–1553
11. Trudeau K, Roy S, Guo W, Trudeau K, Roy S, Guo W (2011) Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci 52:6348–6354
12. Miranda S, González-Rodríguez A, García-Ramírez M, Revuelta-Cervantes J, Hernández C, Simó R, Valverde AM (2012) Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol 227:2352–2362
13. Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, Lyons TJ, Ma JX (2013) Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 62:261–272
14. Barber AJ, Gardner TW, Abcouwer SF (2011) The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci 52:1156–1163
15. Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2012) Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 96:1285–1290
16. Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2014) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 25:23–33
17. Carrasco E, Hernandez C, Miralles A, Huguet P, Farres J, Simo R (2007) Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 30:2902–2908
18. Carrasco E, Hernández C, de Torres I, Farrés J, Simó R (2008) Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis 4:1496–1502
19. Garcia-Ramírez M, Hernández C, Villarroel M, Canals F, Alonso MA, Fortuny R, Masmiquel L, Navarro A, García-Arumí J, Simó R (2009) Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 52:2633–2641
20. Barnstable CJ (1993) Glutamate and GABA in retinal circuitry. Curr Opin Neurobiol 3:520–525
21. Li Q, Puro DG (2002) Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci 43:3109–3116
22. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34(Pt 6):1341–1346
23. Anderson PJ, Watts H, Hille C, Philpott K, Clark P, Gentleman MC, Jen LS (2008) Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat. Clin Ophthalmol 2:801–816
24. Marmor MF, Holder GE, Seeliger MW, Yamamoto S, International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107–114
25. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK (2005) Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54:3119–3125
26. Tang L, Zhang Y, Jiang Y, Willard L, Ortiz E, Wark L, Medeiros D, Lin D (2011) Dietary wolfberry ameliorates retinal structure abnormalities in db/db mice at the early stage of diabetes. Exp Biol Med (Maywood) 236:1051–1063
27. Xiao C, He M, Nan Y, Zhang D, Chen B, Guan Y, Pu M (2012) Physiological effects of superoxide dismutase on altered visual function of retinal ganglion cells in db/db mice. PLoS One 7:e30343
28. Simó R, Bogdanov P, Corraliza L, Carvalho AR, Hernández C (2013) The C57BL/KsJ-db/db mouse: an appropriate model for investigating diabetes-induced retinal neurodegeneration. Diabetologia 56(Suppl 1):S486
29. Hernández C, García-Ramírez M, Corraliza L, Fernández-Carneado J, Farrera-Sinfreu J, Ponsati B, González-Rodríguez A, Valverde AM, Simó R (2013) Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 62:2569–2578
30. Wang L, Deng QQ, Wu XH, Yu J, Yang XL, Zhong YM (2013). Upregulation of Glutamate-Aspartate Transporter by Glial Cell Line-Derived Neurotrophic Factor Ameliorates Cell Apoptosis in Neural Retina in Streptozotocin-Induced Diabetic Rats. CNS Neurosci Ther. doi:10.1111/cns.12150
31. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM (1988) Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 47:815–820
32. Lieth E, LaNoue KF, Antonetti DA, Ratz M (2000) Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The Penn State Retina Research Group. Exp Eye 70:723–730
33. Kowluru RA, Engerman RL, Case GL, Kern TS (2001) Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 38:385–390
34. Pulido JE, Pulido JS, Erie JC, Arroyo J, Bertram K, Lu MJ, Shippy SA (2007) A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res 2007:36150
35. Ambati J, Chalam KV, Chawla DK, D’Angio CT, Guillet EG, Rose SJ, Vanderlinde RE, Ambati BK (1997) Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 115:1161–1166
36. Rauen T, Rothstein JD, Wässle H (1996) Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res 286:325–336
37. Sarthy VP, Pignataro L, Pannicke T, Weick M, Reichenbach A, Harada T, Tanaka K, Marc R (2005) Glutamate transport by retinal Muller cells in glutamate/aspartate transporter-knockout mice. Glia 49:184–196
38. Deplanque D, Gelé P, Pétrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264–6271
39. Arai K, Ikegaya Y, Nakatani Y, Kudo I, Nishiyama N, Matsuki N (2001) Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neural vulnerability. Eur J Neurosci 13:2319–2323